Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanizati... (g results provide further validation of ...)

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process

Date:9/4/2007

g results provide further validation of lipidomic-based therapeutics as an important new area of drug discovery. Lpath was one of the first companies to recognize that bioactive-lipid-signaling molecules, like S1P and LPA, could be excellent targets for rational drug design. By pursuing these targets and demonstrating compelling efficacy, we've opened up an entire class of lipidomic-based therapeutics for the treatment of cancer, diabetes, neurodegenerative disorders, immune function, inflammation, pain, mental disorders, and cardiovascular disease."

Scientists now believe that there are over 1,000 members of the functional lipidome, each of which is a new potential target for therapeutic intervention.

About Lpath:

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases. ASONEP(TM) (the systemic formulation of humanized form of Sphingomab(TM)) is an antibody against S1P that holds promise for the treatment of cancer and other diseases. A second product candidate, iSONEP(TM) (the ocular formulation of humanized Sphingomab), has demonstrated superior results in various preclinical AMD and retinopathy models. Lpath's third product candidate, Lpathomab(TM), is an antibody against LPA, a key bioactive lipid that has been long recognized as a valid disease target. The company's unique ability to generate novel antibodies against bioactive lipids is based on its ImmuneY2(TM) drug-discovery engine, which the company is using to add to its pipeline. For more information, visit http://www.Lpath.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer

Post Your Comments:

Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanizati...(g results provide further validation of ...),Health